TY - JOUR
T1 - Association of the hospital readmissions reduction program implementation with readmission and mortality outcomesin heart failure
AU - Gupta, Ankur
AU - Allen, Larry A.
AU - Bhatt, Deepak L.
AU - Cox, Margueritte
AU - DeVore, Adam D.
AU - Heidenreich, Paul A.
AU - Hernandez, Adrian F.
AU - Peterson, Eric D.
AU - Matsouaka, Roland A.
AU - Yancy, Clyde W.
AU - Fonarow, Gregg C.
N1 - Funding Information:
Funding/Support: This study was funded in part by grant 5T32HL094301-07 from the NIH and by a Young Investigator seed grant award to Dr Gupta from the AHA GWTG-HF program. The GWTG-HF is sponsored in part by Amgen Cardiovascular and has been supported in the past by Medtronic, GlaxoSmithKline, Ortho-McNeil, and the AHA Pharmaceutical Roundtable.
Funding Information:
completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Allen reported receiving funding from the National Institutes of Health (NIH), PCORI, and American Heart Association (AHA) as well as consulting fees from Novartis and Janssen. Dr Bhatt reported being on the advisory board of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; being on the board of directors of Boston VA Research Institute and Society of Cardiovascular Patient Care; being chair of the AHA Quality Oversight Committee; serving on the Data Monitoring Committees of the Cleveland Clinic, Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, and Population Health Research Institute; receiving honoraria from the American College of Cardiology, Belvoir Publications, Duke Clinical Research Institute, Harvard Clinical Research Institute, HMP Communications, Journal of the American College of Cardiology, Slack Publications, Society of Cardiovascular Patient Care, WebMD, Clinical Cardiology, NCDR-ACTION Registry Steering Committee, and VA CART Research and Publications Committee; receiving research funding from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, and The Medicines Company; receiving royalties from Elsevier; being a site coinvestigator for Biotronik, Boston Scientific, and St. Jude Medical (now Abbott); being a trustee for the American College of Cardiology; and conducting unfunded research for FlowCo, Merck, PLx Pharma, and Takeda. Dr DeVore reported receiving research support from the AHA, Amgen, and Novartis as well as being a consultant with Novartis. Dr Fonarow reported receiving research support from the NIH; consulting with Abbott, Amgen, Novartis, and Medtronic; and serving as a member of the AHA Get With The Guidelines-Heart Failure (GWTG-HF) Steering Committee. No other disclosures were reported.
Publisher Copyright:
© 2017 American Medical Association. All rights reserved.
PY - 2018/1
Y1 - 2018/1
N2 - IMPORTANCE Public reporting of hospitals' 30-day risk-standardized readmission rates following heart failure hospitalization and the financial penalization of hospitals with higher rates have been associated with a reduction in 30-day readmissions but have raised concerns regarding the potential for unintended consequences. OBJECTIVE To examine the association of the Hospital Readmissions Reduction Program (HRRP) with readmission and mortality outcomes among patients hospitalized with heart failure within a prospective clinical registry that allows for detailed risk adjustment. DESIGN, SETTING, AND PARTICIPANTS Interrupted time-series and survival analyses of index heart failure hospitalizations were conducted from January 1, 2006, to December 31, 2014. This study included 115 245 fee-for-service Medicare beneficiaries across 416 US hospital sites participating in the American Heart Association Get With The Guidelines-Heart Failure registry. Data analysis took place from January 1, 2017, to June 8, 2017. EXPOSURES Time intervals related to the HRRP were before the HRRP implementation (January 1, 2006, to March 31, 2010), during the HRRP implementation (April 1, 2010, to September 30, 2012), and after the HRRP penalties went into effect (October 1, 2012, to December 31, 2014). MAIN OUTCOMES AND MEASURES Risk-Adjusted 30-day and 1-year all-cause readmission and mortality rates. RESULTS The mean (SD) age of the study population (n = 115 245) was 80.5 (8.4) years, 62 927 (54.6%) were women, and 91 996 (81.3%) were white and 11 037 (9.7%) were black. The 30-day risk-Adjusted readmission rate declined from 20.0%before the HRRP implementation to 18.4%in the HRRP penalties phase (hazard ratio (HR) after vs before the HRRP implementation, 0.91; 95%CI, 0.87-0.95; P < .001). In contrast, the 30-day risk-Adjusted mortality rate increased from 7.2%before the HRRP implementation to 8.6%in the HRRP penalties phase (HR after vs before the HRRP implementation, 1.18; 95%CI, 1.10-1.27; P < .001). The 1-year risk-Adjusted readmission and mortality rates followed a similar pattern as the 30-day outcomes. The 1-year risk-Adjusted readmission rate declined from 57.2%to 56.3%(HR, 0.92; 95%CI, 0.89-0.96; P < .001), and the 1-year risk-Adjusted mortality rate increased from 31.3%to 36.3%(HR, 1.10; 95%CI, 1.06-1.14; P < .001) after vs before the HRRP implementation. CONCLUSIONS AND RELEVANCE Among fee-for-service Medicare beneficiaries discharged after heart failure hospitalizations, implementation of the HRRP was temporally associated with a reduction in 30-day and 1-year readmissions but an increase in 30-day and 1-year mortality. If confirmed, this findingmay require reconsideration of the HRRP in heart failure.
AB - IMPORTANCE Public reporting of hospitals' 30-day risk-standardized readmission rates following heart failure hospitalization and the financial penalization of hospitals with higher rates have been associated with a reduction in 30-day readmissions but have raised concerns regarding the potential for unintended consequences. OBJECTIVE To examine the association of the Hospital Readmissions Reduction Program (HRRP) with readmission and mortality outcomes among patients hospitalized with heart failure within a prospective clinical registry that allows for detailed risk adjustment. DESIGN, SETTING, AND PARTICIPANTS Interrupted time-series and survival analyses of index heart failure hospitalizations were conducted from January 1, 2006, to December 31, 2014. This study included 115 245 fee-for-service Medicare beneficiaries across 416 US hospital sites participating in the American Heart Association Get With The Guidelines-Heart Failure registry. Data analysis took place from January 1, 2017, to June 8, 2017. EXPOSURES Time intervals related to the HRRP were before the HRRP implementation (January 1, 2006, to March 31, 2010), during the HRRP implementation (April 1, 2010, to September 30, 2012), and after the HRRP penalties went into effect (October 1, 2012, to December 31, 2014). MAIN OUTCOMES AND MEASURES Risk-Adjusted 30-day and 1-year all-cause readmission and mortality rates. RESULTS The mean (SD) age of the study population (n = 115 245) was 80.5 (8.4) years, 62 927 (54.6%) were women, and 91 996 (81.3%) were white and 11 037 (9.7%) were black. The 30-day risk-Adjusted readmission rate declined from 20.0%before the HRRP implementation to 18.4%in the HRRP penalties phase (hazard ratio (HR) after vs before the HRRP implementation, 0.91; 95%CI, 0.87-0.95; P < .001). In contrast, the 30-day risk-Adjusted mortality rate increased from 7.2%before the HRRP implementation to 8.6%in the HRRP penalties phase (HR after vs before the HRRP implementation, 1.18; 95%CI, 1.10-1.27; P < .001). The 1-year risk-Adjusted readmission and mortality rates followed a similar pattern as the 30-day outcomes. The 1-year risk-Adjusted readmission rate declined from 57.2%to 56.3%(HR, 0.92; 95%CI, 0.89-0.96; P < .001), and the 1-year risk-Adjusted mortality rate increased from 31.3%to 36.3%(HR, 1.10; 95%CI, 1.06-1.14; P < .001) after vs before the HRRP implementation. CONCLUSIONS AND RELEVANCE Among fee-for-service Medicare beneficiaries discharged after heart failure hospitalizations, implementation of the HRRP was temporally associated with a reduction in 30-day and 1-year readmissions but an increase in 30-day and 1-year mortality. If confirmed, this findingmay require reconsideration of the HRRP in heart failure.
UR - http://www.scopus.com/inward/record.url?scp=85041469787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041469787&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2017.4265
DO - 10.1001/jamacardio.2017.4265
M3 - Article
C2 - 29128869
AN - SCOPUS:85041469787
SN - 2380-6583
VL - 3
SP - 44
EP - 53
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 1
ER -